ECTRIMS 2019: Effect of initial high-efficacy disease modifying therapy in relapsing-remitting MS

Mathias Buron | ECTRIMS 2019 | Septttember 13, 2019

Föreläsare: Mathias Buron

Patients with MS are often initially treated with moderately effective disease modifying therapies, and in case of insufficient treatment response therapy is escalated to high efficacy disease modifying therapies. In this MEDtalk Mathias Due Buron present Danish data for difference of disease activity in patients started initially on high efficacy disease modifying therapies compared to similar patients started moderately effective disease modifying therapies.